According to the latest report published by Credence Research, Inc. “Bronchitis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global Bronchitis Treatment market was valued at USD 3,345.8 Mn in 2017, and is expected to reach USD 4,606.3 Mn by 2026, expanding at a CAGR of 4.9% from 2018 to 2026.
Browse the full report at Bronchitis Treatment Market
Market Insights
Bronchitis is one of the most common respiratory diseases observed in developed as well as developing countries. Chronic bronchitis is life-threatening most of the times and the Centers for Disease Control and Prevention recorded that 8.6 million people were diagnosed with chronic bronchitis in year 2016 in the U.S with 0.2% of mortality. However, as the U.S is more developed country mortality rate is low but in developing and under developed countries the mortality rate is in range of 3% – 4%. Bronchitis is triggered due to several factors common cold & flu, and other bacterial infections which leads to airway obstruction due to inflammation of bronchial walls. A patient suffering with acute bronchitis takes 1 to 2 weeks to recover while in case of chronic bronchitis it takes 2 to 3 months. However, overall drug pipeline of bronchitis treatment is strong as there are several combination therapies present that provide target-specific performance.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/59646
In 2017, bronchodilators was identified as the largest growing segment in bronchitis treatment market due to key factors such as rising prevalence related to bronchitis, and increasing awareness campaigns related to chronic bronchitis, & other bacterial infections in developed & developing countries. The awareness activities carried out in developing and under developed countries have helped to increase the diagnosis rate in last couple of years. Bronchodilators are always the first-line drugs for treatment of bronchitis as the clearing airway obstruction is the most important thing in chronic bronchitis to ease the breathing of patient.
North America was observed as the largest bronchitis treatment market due to rising prevalence coupled with high prevalence of bronchitis, and increasing trend of smoking in young generation have assisted the slight rise in the prevalence rate, developed & accessible diagnostic technologies. According to Pharmaprix, about 1 in 20 people suffers with chronic bronchitis in the North America. In addition to this, North America bronchitis market is also growing due to ongoing development in research of bronchitis treatment drug pipeline.
Market Competition Assessment:
The bronchitis treatment market is growing at steadily and major companies operating in this market are developing treatments that are safe and target-specific. The major companies available in the global market are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.
Key Market Movements:
- Rising awareness and prevalence related to bronchitis treatment & diagnosis expected to assist the market growth
- Incessant growth in research & development of bronchitis treatment will assist the growth in demand for safe & efficient treatment options
- Mounting diagnosis rate related to developing countries will increase the demand for bronchitis treatment market
- Strong drug pipeline expected to increase the CAGR of the overall market in the near future
Inquiry before Buying: https://www.credenceresearch.com/inquiry-before-buying/59646
Table of content
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Bronchitis Treatment Market Portraiture
2.2. Global Bronchitis Treatment Market, by Type of Drug Class, 2017 (US$ Mn)
2.3. Global Bronchitis Treatment Market, by Geography, 2017 Vs 2026 (Value %)
2.1. Global Bronchitis Treatment Market Portraiture
2.2. Global Bronchitis Treatment Market, by Type of Drug Class, 2017 (US$ Mn)
2.3. Global Bronchitis Treatment Market, by Geography, 2017 Vs 2026 (Value %)
Chapter 3. Global Bronchitis Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. Increasing prevalence and awareness related to bronchitis in developed as well as developing countries
3.2.2. Rising cases of respiratory diseases triggered due to air-pollutants or cigarette smoke
3.3. Challenges
3.3.1. Initial stages of bronchitis are most of the times treated with traditional medicines in Asia Pacific
3.4. Opportunities
3.4.1. Strong pipeline and continuous research and development in the field of bronchitis treatment
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017
3.1. Market Overview
3.2. Drivers
3.2.1. Increasing prevalence and awareness related to bronchitis in developed as well as developing countries
3.2.2. Rising cases of respiratory diseases triggered due to air-pollutants or cigarette smoke
3.3. Challenges
3.3.1. Initial stages of bronchitis are most of the times treated with traditional medicines in Asia Pacific
3.4. Opportunities
3.4.1. Strong pipeline and continuous research and development in the field of bronchitis treatment
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017
Chapter 4. Global Bronchitis Treatment Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Antitussives/ Expectorants
4.3. Bronchodilators
4.4. Beta-adrenergic Agonist
4.5. Systemic Corticosteroids
4.6. Inhaled Corticosteroids
4.7. Phosphodiesterase-4 Inhibitors
4.8. Analgesics
4.9. Antibiotics
4.1. Overview
4.2. Antitussives/ Expectorants
4.3. Bronchodilators
4.4. Beta-adrenergic Agonist
4.5. Systemic Corticosteroids
4.6. Inhaled Corticosteroids
4.7. Phosphodiesterase-4 Inhibitors
4.8. Analgesics
4.9. Antibiotics
Chapter 5. Global Bronchitis Treatment Market: Pipeline Analysis
5.1. Overview
5.2. Phase III [Till 2026] (U$ Mn)
5.2.1. Extracorporeal Photopheresis (ECP)
5.2.2. Cyclosporine
5.3. Phase II (Qualitative Information)
5.3.1. Alteplase
5.3.2. Alvelestat
5.3.3. CKD-497
5.3.4. Treatment-inhaled tPA
5.4. Phase I (Qualitative Information)
5.4.1. HOB-051
5.4.2. Pirfenidone
5.4.3. Aerosolized Infasurf
5.1. Overview
5.2. Phase III [Till 2026] (U$ Mn)
5.2.1. Extracorporeal Photopheresis (ECP)
5.2.2. Cyclosporine
5.3. Phase II (Qualitative Information)
5.3.1. Alteplase
5.3.2. Alvelestat
5.3.3. CKD-497
5.3.4. Treatment-inhaled tPA
5.4. Phase I (Qualitative Information)
5.4.1. HOB-051
5.4.2. Pirfenidone
5.4.3. Aerosolized Infasurf
Download Request Free Customization: https://www.credenceresearch.com/request-for-customization/59646
Our Blog: http://www.tcnindustry.com/
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
Toll Free (US/CANADA) Ph.: +1-800-361-8290
E-mail: sales@credenceresearch.com
Website: http://www.credenceresearch.com
No comments:
Post a Comment